Full Press Release Details
MEDIA ADVISORY, June 26, 2006 (PRIMEZONE) --
Douglas Michels, President and CEO of OraSure Technologies,
Inc. (OSUR), will join New York City Mayor Michael Bloomberg,
Frank J. Oldham Jr., Executive Director, the National
Association of People with AIDS (NAPWA), and Regan Hofmann,
member of the NAPWA Board of Directors and Editor-in-Chief
of POZ Magazine, to preside over the opening bell in observance
of the twelfth annual National HIV Testing Day (NHTD). This
important observance is a campaign led by NAPWA to encourage
at-risk individuals to receive voluntary HIV counselling and
OraSure Technologies is the manufacturer of the OraQuick(r)
ADVANCE(tm) Rapid HIV-1/2 Antibody Test, the only U.S.
FDA-approved rapid, HIV-1/2 test that can be used with oral
fluid, whole blood and plasma and produce results in 20 minutes.
The Centers for Disease Control and Prevention (CDC) reports
that as many as one-third of the estimated one million HIV-
infected people in the United States may be unaware that they
are infected with the HIV virus. HIV counseling and testing
enables people with HIV to take steps to protect their own health
and that of their partners, and helps people who test negative
get the information they need to stay uninfected.
NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway
Tuesday, June 27, 2006 at 9:30 a.m. EDT
Erika Freed; 917-359-7974
Stephanie Lowenthal; 646-441-5220
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA-5 C-band/transponder 14. The downlink frequency is 3980 horizontal; audio: 6.2/6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About OraSure Technologies
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.
OraSure Technologies is the leading supplier of oral-fluid collection devices and assays to hospitals, the life insurance industry and public health markets for the detection of HIV. In addition, the Company supplies oral-fluid testing solutions for drugs of abuse testing. For more information on the Company, please go to http://www.orasure.com.